Kypha
Saint Louis
About Kypha
Kypha is an early-stage life sciences company developing leading-edge technology and clinically useful products to improve the way autoimmune and inflammatory disorders are monitored and treated. With a core team of nine, plus an extensive network of scientific advisors, clinical collaborators and business mentors, Kypha has leveraged Federal grants and raised more than $3 million in private capital since 2011 to advance its lead diagnostic product – Comp Act Dx – toward FDA clearance and commercial launch in early 2014. Comp Act Dx is a simple yet revolutionary test that quickly measures the level of inflammation in the body – such as that caused by traumatic injury or autoimmune disease – with an unprecedented combination of speed and accuracy. Comp Act Dx is designed to allow superior monitoring of at-risk patients by measuring changes in inflammation in near-real time, thereby aiding medical professionals in making earlier, more effective clinical intervention decisions.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $24.0M
- Last round: Series Unknown (May 2022)
- Website: kypha.net
- Phone: 314-282-2008
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/kypha-67590 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.